|
Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division.
|
| | | Contact Information | |
Address: |
Route 22 West
Somerville, NJ 08876
| | Phone: | 908-218-0707 | | Fax: | 908-218-2471 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman:
Larry Ellberger
| | • |
CEO and Director:
Robert Taub
| | • |
President and COO:
Nissim Mashiach
|
|
|
